CNT: A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder

Sponsor
Auburn University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05621538
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
90
1
5
32
2.8

Study Details

Study Description

Brief Summary

The goal of this clinical study is to test the effectiveness of a supplemental fMRI neurofeedback and/or TMS intervention in individuals seeking treatment for Alcohol Use Disorder.

After an initial visit, participants will come in once a week for four (4) weeks for an intervention session, which may or may not include TMS and MRI. Participants will be contacted for monthly follow-ups (remotely) for up to 12 months and will be asked to come in for two MRI follow-ups at 6 and 12 months.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Realtime fMRI Neurofeedback - Active
  • Device: TMS - Active
  • Behavioral: Realtime fMRI Neurofeedback - Yoked Sham
  • Device: TMS - Sham
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
The PI will prospectively assign treatment groups with blind codes and so will not be blind to treatment type. Other staff, who are the individuals primarily working with the patients and who will be conducting follow-up interviews, will be blind to treatment type. It is not possible to blind the 5th condition (treatment as usual with a brief check-in).
Primary Purpose:
Treatment
Official Title:
A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Jan 31, 2025
Anticipated Study Completion Date :
Jan 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Neurofeedback-active + TMS-active

4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)

Behavioral: Realtime fMRI Neurofeedback - Active
fMRI aided reinforcement of craving regulation

Device: TMS - Active
rTMS to right dorsolateral prefrontal cortex to reduce craving
Other Names:
  • Magventure Magpro
  • Active Comparator: Neurofeedback-active + TMS-sham

    4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)

    Behavioral: Realtime fMRI Neurofeedback - Active
    fMRI aided reinforcement of craving regulation

    Device: TMS - Sham
    rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex

    Active Comparator: Neurofeedback-sham + TMS-active

    4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)

    Device: TMS - Active
    rTMS to right dorsolateral prefrontal cortex to reduce craving
    Other Names:
  • Magventure Magpro
  • Behavioral: Realtime fMRI Neurofeedback - Yoked Sham
    Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation

    Sham Comparator: Neurofeedback-sham + TMS-sham

    4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)

    Behavioral: Realtime fMRI Neurofeedback - Yoked Sham
    Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation

    Device: TMS - Sham
    rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex

    No Intervention: Check-In Only

    4 sessions of: Completing typical pre-TMS/MRI procedures Being prompted to reflect on outside treatment (TAU)

    Outcome Measures

    Primary Outcome Measures

    1. Change in Alcohol Use over Time [Assessed at weeks: 1 (baseline), 2-5 (intervention sessions, pre and post), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)]

      Alcohol Timeline Followback (alc-TLFB)

    2. Change in Alcohol Craving over Time [Assessed at weeks: 1 (baseline), 2-5 (intervention sessions, pre and post), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)]

      Alcohol Craving Questionnaire (ACQ)

    3. Change in Community Functioning over Time [Assessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)]

      Drinker Inventory of Consequences (DrInC)

    4. Change in Employment Status over Time [Assessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)]

      self-reported employment status

    5. Change in Aggression and Victimization over Time [Assessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57 (follow-ups)]

      Revised Conflict Tactics Scales (CTS-R)

    6. Change in Antisocial Behavior over Time [Assessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57 (follow-ups)]

      number of self-reported contacts with the police, convictions, and other criminal behaviors

    7. Change in Brain Activity during Alcohol Cue Presentation over Time [Assessed at weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)]

      Measured via fMRI; standard alcohol cue reactivity

    8. Change in Brain Activity during Simultaneous Sociomoral & Alcohol Cue Presentation over Time [Assessed at weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)]

      Measured via fMRI; alcohol-cued sociomoral processing

    Secondary Outcome Measures

    1. Change in Brain Gray Matter Structure over Time [Weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)]

      Measured via MRI; gray matter volume

    2. Change in Brain White Matter Structure over Time [Weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)]

      Measured via MRI; white matter diffusion

    3. Change in Resting State Functional Connectivity over Time [Weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)]

      Measured via fMRI

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age 19-65

    2. Receiving treatment for Alcohol Use Disorder

    Exclusion Criteria:
    1. MRI Contraindications

    2. Presence of metal in the body that would make having a 7T MRI unsafe (including facial tattoos)

    3. Claustrophobia, such that individual would be unable to stay in the MRI for up to 1 hr

    4. Hearing loss, including tinnitus, that might be made worse by MRI or TMS

    5. TMS Contraindications

    6. Has ever had a seizure, or has a family history of epilepsy

    7. Taking medications or substances that lower the seizure threshold

    8. Implanted devices that are in the head or rely on physiological signals

    9. History of neurological disease, such as stroke or brain tumor

    10. Head injury with loss of consciousness greater than 30 minutes

    11. Actively withdrawing from alcohol

    12. Family history of schizophrenia or presence of psychotic symptoms

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Auburn University Auburn Alabama United States 36849

    Sponsors and Collaborators

    • Auburn University
    • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    Investigators

    • Principal Investigator: Samantha J Fede, PhD, Auburn University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Samantha Fede, Assistant Professor, Auburn University
    ClinicalTrials.gov Identifier:
    NCT05621538
    Other Study ID Numbers:
    • 22145
    • R00AA027830
    First Posted:
    Nov 18, 2022
    Last Update Posted:
    Nov 18, 2022
    Last Verified:
    Nov 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Keywords provided by Samantha Fede, Assistant Professor, Auburn University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 18, 2022